News Release

IMpower010 shows significantly improved disease-free survival for patients with resected stage II to III non-small cell lung cancer

Reports and Proceedings

International Association for the Study of Lung Cancer

(Denver September 9, 2021 9 a.m. GMT/10 a.m. CDT/11 a.m. EDT)-- The Phase III IMpower010 trial evaluating atezolizumab vs best supportive care after surgical resection and adjuvant chemotherapy met its primary endpoint showing significant disease-free survival improvement for patients with stage II-IIIA (UICC v7) non-small cell lung cancer. Study results were presented today at the IASLC 2021 World Conference on Lung Cancer. 

At the interim disease-free survival  analysis, the trial’s primary endpoint, showed a significant disease-free survival benefit with atezolizumab compared with best supportive care after complete resection and adjuvant chemotherapy in patients with PD-L1 TC ≥1% stage II-IIIA NSCLC and in all randomized patients with stage II-IIIA NSCLC; the significance boundary for disease-free survival was not crossed in the intent-to-treat (ITT) population (stage IB-IIIA NSCLC).  

Atezolizumab was well tolerated, and no new safety signals were identified. In their current presentation, the investigators examined the impact of therapies prior to adjuvant atezolizumab, including the extent of pulmonary resection, the type of mediastinal nodal assessment and adjuvant chemotherapy regimens, on disease-free survival. These pre-randomization variables as well as the time from surgery to adjuvant treatment are topics of interest, according to Nasser Altorki, M.D., of New York-Presbyterian Hospital, Weill Cornell Medicine in New York City. 

Altorki and co-investigators across 22 countries and regions enrolled 1280 patients with completely resected stage IB (tumors ≥4 cm)-IIIA NSCLC (AJCC/UICC v7) and an ECOG performance status of 0-1. Patients received up to four 21-day cycles of cisplatin-based chemotherapy, and 1005 patients were subsequently randomized 1:1 to atezolizumab 1200 mg every three weeks (16 cycles or until disease recurrence or unacceptable toxicity) or best supportive care. The primary endpoint of investigator-assessed disease-free survival was tested hierarchically in the PD-L1 TC ≥1% (SP263) stage II-IIIA population, all-randomized stage II-IIIA population, and ITT population (stage IB-IIIA).  

Surgery type, disease stage, mediastinal nodal assessment, and cisplatin-based chemotherapy regimens were well balanced between the atezolizumab and best supportive care arms. In the ITT population, the most common surgery was lobectomy (78.1%); 15.9% had pneumonectomy and 5.0% had bilobectomy. Mediastinal lymph node dissection or sampling was performed in 80.7% and 18.0% of patients, respectively. The majority of patients (76%-95%) across different chemotherapy treatments in both arms received the planned 4 cycles of chemotherapy. 

In the ITT population, median time from surgery to first atezolizumab treatment or best supportive care was 5.2 months (range, 2.4-7.7) and 5.1 months (range, 2.3-8.0), respectively. In this exploratory analysis, the forest plots showed that disease-free survival in the PD-L1 TC ≥1% stage II-IIIA and all-randomized stage II-IIIA populations favored the atezolizumab vs best supportive care arm across most disease stages, surgery types, and chemotherapy regimens.  

“Patients who participated in the IMpower010 trial, including patients with nodal involvement, saw benefit across disease stages (stage II-IIIA sub-populations),” Altorki reported. 


About the IASLC: 

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit for more information.  

About the WCLC: 

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several 

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.